Frovatriptan succinate hydrate Inhibitor

Name: Frovatriptan succinate hydrate Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5753144
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753144

Frovatriptan succinate hydrate is effective in treating the full spectrum of migraine including the associated symptoms of nausea, vomiting, photophobia, and phonophobia. Frovatriptan succinate hydrate can also be used as in mini-prophylaxis in menstrual… More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Frovatriptan succinate hydrate, Inhibitor

Full Product Name

Frovatriptan succinate hydrate

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

379.41

Solubility

<1mg/ml refers to the product slightly soluble or insoluble

Formula

C18H25N3O6

SMILES

O=C(O)CCC(O)=O.O=C(C1=CC2=C(NC3=C2C[C@H](NC)CC3)C=C1)N.O

CAS Number

158930-17-7

Target & IC50

5-HT1B Receptor: ic50 8.6 (pki)
5-HT1D Receptor: ic50 8.4 (pki)
Human 5-HT7 Receptor: ic50 6.7 (pki)

In Vitro

Frovatriptan has a high affinity for 5-HT1B and 5-HT1D receptors and a moderate affinity for the 5-HT1A and 5-HT1F receptors subtypes. Frovatriptan has a moderate affinity for the 5-HT7 receptors, an action associated with coronary artery relaxation in the dog.Cerebral vasodilatation and neurogenic inflammation are considered to be prime movers in the pathogenesis of migraine. Activation of 5-HT1B reverses cerebral vasodilatation and activation of 5-HT1D prevents neurogenic inflammation.

Product Categories/Family for Frovatriptan succinate hydrate, inhibitor

GPCR/G Protein; 5-HT Receptor; Neuroscience

Product References and Citations for Frovatriptan succinate hydrate, inhibitor

Kelman L. Review of frovatriptan in the treatment,of migraine. Neuropsychiatr Dis Treat. 2008 Feb;4(1):49-54.
Kelman L. Review of frovatriptan in the treatment,of migraine. Neuropsychiatr Dis Treat. 2008 Feb;4(1):49-54.
Comer MB. Et al. Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. Headache. 2002 Apr;42 Suppl 2:S47-53.
Comer MB. Et al. Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. Headache. 2002 Apr;42 Suppl 2:S47-53.

Other Notes

Small volumes of Frovatriptan succinate hydrate, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Frovatriptan succinate hydrate purchase

MBS5753144 is an inhibitor targeting Frovatriptan succinate hydrate.